+A -A

Tabela:
Comparative View:

2Q17 Create chart
Net sales revenues 916,724
Change in Fair Value of Biological Assets 38,582
Cost of Goods Sold -587,806
Depreciation / Amortization / exhaustion -94,810
Exhaustion of biological assets -27,384
Gross Profit 245,306
Selling Expenses -153,004
General and Administrative Expenses -35,198
Management Compensation -3,893
Other Operating Compensation 32,883
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 86,094
Financial Income 44,598
Financial Expenses -103,682
Income Before Income Tax and Social Contribution 27,010
Income and social contribution taxes - current -7,120
Income Tax and Social Contribution - Deferred 4,877
Effect profit from discontinued operation 0
Net Income 24,767
Recurring Net Income 24,767
Recurring EBITDA 178,097
EBITDA Margin 19.4 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza